Therasphere
Therasphere is a medical device with 20 clinical trials. Currently 2 active trials ongoing. Historical success rate of 83.3%.
Success Metrics
Based on 10 completed trials
Phase Distribution
Phase Distribution
3
Early Stage
2
Mid Stage
1
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
76.9%
10 of 13 finished
23.1%
3 ended early
2
trials recruiting
20
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Combined Y-90 Selective Internal Radiation Therapy (Y-90 SIRT) and Stereotactic Body Radiation Therapy (SBRT) in Hepatic Malignancy.
A Post Approval Study to Evaluate Safety and Effectiveness of Multicompartmental Dosimetry Planning.
A Study of Selective Internal Radiation Therapy for the Management of Chemotherapy-induced Thrombocytopenia With Splenomegaly in Adult Subjects With Gastrointestinal Cancer
Non-Interventional Registry Study to Evaluate the Effectiveness of TheraSphere® in the Treatment of Hepatocellular Carcinoma (HCC)
Building Evidence for Ablative Internal Radiation Therapy in Localized HCC Beyond the Up-To-7 Criteria
Clinical Trials (20)
Combined Y-90 Selective Internal Radiation Therapy (Y-90 SIRT) and Stereotactic Body Radiation Therapy (SBRT) in Hepatic Malignancy.
A Post Approval Study to Evaluate Safety and Effectiveness of Multicompartmental Dosimetry Planning.
A Study of Selective Internal Radiation Therapy for the Management of Chemotherapy-induced Thrombocytopenia With Splenomegaly in Adult Subjects With Gastrointestinal Cancer
Non-Interventional Registry Study to Evaluate the Effectiveness of TheraSphere® in the Treatment of Hepatocellular Carcinoma (HCC)
Building Evidence for Ablative Internal Radiation Therapy in Localized HCC Beyond the Up-To-7 Criteria
TheraSphere for the Treatment of Unresectable Hepatocellular Carcinoma
Transarterial Radioembolization (TARE) in COlorectal MEtastasis of Liver
TheraSphere® for Treatment of Unresectable Hepatocellular Carcinoma
Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer
Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer
Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot be Removed by Surgery
Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer
TheraSphere & Treatment of Unresectable Primary or Unresectable Secondary Liver Cancer
RadioEmbolization for the ADvancement of Y90 Glass Microspheres Registry
Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein
A TheraSphere® Advanced Dosimetry Retrospective Global Study in HCC
A Treatment of Unresectable Hepatocellular Carcinoma With TheraSphere®
A Humanitarian Device Exemption Treatment Protocol of TheraSphere For Treatment of Unresectable Hepatocellular Carcinoma
Phase 1 TheraSphere + Everolimus With Neuroendocrine Tumors (NETs) + Liver Only or Liver Dominant Disease
TheraSpheres Treatment for Unresectable Hepatocarcinoma and Portal Vein Thrombosis
All 20 trials loaded
Drug Details
- Intervention Type
- DEVICE
- Total Trials
- 20